Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A119KH | ISIN: IL0011319527 | Ticker-Symbol: 1BT
Tradegate
28.08.25 | 15:25
0,920 Euro
+2,79 % +0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENLIVEX THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ENLIVEX THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,9050,94530.08.
0,8750,91529.08.

Aktuelle News zur ENLIVEX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEnlivex Therapeutics Ltd. - 6-K, Report of foreign issuer2
18.08.Enlivex stock soars after positive knee osteoarthritis trial data17
18.08.Enlivex Therapeutics Ltd: Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis232ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee...
► Artikel lesen
15.08.Stocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers424SANTA CLARA (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
14.08.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer9
28.07.Enlivex Therapeutics Ltd: Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data17
ENLIVEX THERAPEUTICS Aktie jetzt für 0€ handeln
28.07.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
13.06.RedChip Companies, Inc.: Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV384ORLANDO, FL / ACCESS Newswire / June 13, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics (NASDAQ:ENLV) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big...
► Artikel lesen
10.06.Enlivex Therapeutics Ltd: Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology10
30.05.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer3
30.04.Enlivex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers5
24.04.Enlivex stock holds Buy rating with $7 target from H.C. Wainwright13
21.04.Enlivex Therapeutics Ltd: Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis283Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
► Artikel lesen
21.04.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
03.04.Enlivex Therapeutics Ltd: Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis174Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ...
► Artikel lesen
03.04.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer1
24.03.Enlivex stock price target raised to $7 at H.C. Wainwright1
17.03.Enlivex Therapeutics Ltd: Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis2
17.03.Enlivex Therapeutics Ltd. - 6-K, Report of foreign issuer2
04.03.Enlivex Therapeutics Ltd: Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis1
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1